Ul­tragenyx touts Phase 2 da­ta for Mereo-part­nered rare bone dis­or­der drug as Phase 3 gets un­der­way

Four years af­ter bet­ting up to $304 mil­lion on a drug for a rare ge­net­ic bone dis­or­der, Ul­tragenyx and its part­ner Mereo Bio­Phar­ma re­port­ed pos­i­tive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.